Dermapharm Holding SE (DMP) AI Stock Analysis

• Market Cap: €1.84B
• Dividend Yield: 2.73%
• Average Volume (3M): 16.58K
• Price to Earnings (P/E): 17.5
• Beta (1Y): 0.56
• Revenue Growth: 3.98%
• EPS Growth: 29.10%
• Country: DE
• Employees: 3,610
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.39
• Shares Outstanding: 53,840,000
• 10 Day Avg. Volume: 21,698
• 30 Day Avg. Volume: 16,582
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €37.67
• Price Target Upside: 8.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: €38.00 ▲(9.67% Upside)

Dermapharm Holding SE's overall stock score reflects strong financial performance, particularly in profitability and equity returns, balanced by challenges in revenue growth and cash flow sustainability. The technical analysis indicates a neutral to slightly positive trend, while the valuation suggests the stock is fairly valued with a reasonable P/E ratio and a good dividend yield.

Positive Factors

Cash Flow

Operating cash flow rose significantly due to lower working capital demand.

Earnings

Dermapharm Holding reported a better-than-expected end to the year with a 7% earnings and 4% sales beat in the fourth quarter.

Financial Performance

Adjusted EBITDA grew to €66.7m, translating into a margin of 24.5%, primarily driven by Branded Pharmaceuticals where international and allergology areas continue to drive bottom-line growth.

Negative Factors

Earnings Outlook

The outlook on revenue and earnings sits below consensus with expected low single-digit revisions.

Product Performance

In Other Health Products, there is no turnaround achieved yet with adjusted EBITDA down by 14%.

Sales Performance

Group sales fell by -3% with robust growth in Branded Pharmaceuticals and Other Health Products not covering the shortfall from strategy-induced lower Parallel Import sales.

Dermapharm Holding SE Business Overview & Revenue Model

Company Description

Dermapharm Holding SE (DMP) is a Germany-based pharmaceutical company specializing in the development, production, and marketing of prescription and non-prescription medications. Operating primarily in the pharmacological and over-the-counter (OTC) sectors, Dermapharm focuses on areas such as dermatology, pain management, and other therapeutic segments. The company’s portfolio includes a range of proprietary products and licensed pharmaceuticals that cater to diverse healthcare needs.

How the Company Makes Money

Dermapharm generates revenue through multiple streams, primarily from the sale of its proprietary prescription drugs and OTC products. The company also engages in licensing agreements, allowing it to earn royalties from products developed in collaboration with other pharmaceutical firms. Additionally, Dermapharm benefits from partnerships with healthcare providers and distributors, which facilitate market penetration and broaden its product reach. The company's strategic focus on innovation and product development, alongside its established distribution networks, plays a crucial role in driving its earnings.

Dermapharm Holding SE Financial Statement Overview

Summary

Dermapharm Holding SE shows strong profitability with healthy EBIT and EBITDA margins. However, challenges such as a slight decline in gross profit and reduced free cash flow growth impact the score.

Income Statement

Dermapharm Holding SE shows solid profitability with a gross profit margin of 56.5% and a net profit margin of 8.7% for TTM (Trailing-Twelve-Months). The revenue growth rate over the past year is moderate at 5.8%. EBIT and EBITDA margins are healthy at 18.1% and 25.8%, respectively. However, a slight decline in gross profit from the previous annual period indicates potential cost pressures.

Balance Sheet

The company's balance sheet reflects moderate leverage with a debt-to-equity ratio of 1.56. The equity ratio is relatively stable at 30.2%, suggesting a balanced reliance on debt and equity. ROE for TTM (Trailing-Twelve-Months) is decent at 16.2%. Despite a high level of debt, the company maintains a healthy equity base, but increasing liabilities remain a concern.

Cash Flow

The cash flow analysis shows a contraction in free cash flow growth, with a decrease from the previous period. The operating cash flow to net income ratio is 1.60, indicating strong cash generation relative to net income. However, the free cash flow to net income ratio has decreased, highlighting potential challenges in maintaining cash reserves amidst increased capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.18B	1.14B	1.02B	942.91M	793.83M
Gross Profit	669.35M	767.07M	719.16M	660.83M	620.69M	463.48M
EBITDA	306.09M	320.91M	265.55M	329.81M	358.10M	186.57M
Net Income	103.57M	113.79M	62.37M	134.24M	209.58M	85.83M
Balance Sheet
Total Assets	2.11B	2.08B	2.16B	1.41B	1.41B	1.22B
Cash, Cash Equivalents and Short-Term Investments	118.02M	121.71M	159.54M	161.36M	172.06M	121.66M
Total Debt	995.29M	979.61M	1.08B	516.45M	580.30M	606.80M
Total Liabilities	1.47B	1.47B	1.62B	880.34M	907.13M	899.81M
Stockholders Equity	638.56M	604.42M	539.21M	531.59M	497.32M	321.97M
Cash Flow
Free Cash Flow	124.66M	163.14M	177.88M	249.52M	189.16M	90.30M
Operating Cash Flow	165.91M	201.38M	219.42M	288.53M	250.37M	131.10M
Investing Cash Flow	-32.20M	-29.61M	-415.43M	-99.01M	-129.35M	-105.91M
Financing Cash Flow	-141.96M	-209.17M	204.54M	-199.77M	-80.98M	-14.09M

Dermapharm Holding SE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 34.65
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Positive. The current price of 34.65 is above the 20-day moving average (MA) of 33.21, above the 50-day MA of 33.98, and below the 200-day MA of 36.19, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.11 is Neutral, neither overbought nor oversold. The STOCH value of 82.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DMP.

Dermapharm Holding SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DMP	69 Neutral	€1.84B	17.47	18.49%	2.73%	3.98%	29.10%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
MEDOF	―	$447.33M	21.44	3.56%	―	―	―
PHH2	―	€827.56M	7.63	9.81%	―	―	―
PSG	75 Outperform	€376.80M	18.74	48.46%	0.16%	13.80%	10.94%
93M1	73 Outperform	€76.85M	2.40	12.12%	6.84%	-15.43%	8.45%
APPH	58 Neutral	€92.23M	139.31	2.09%	―	27.42%	―